Amylyx Pharmaceuticals Earnings beat, Revenue misses In Q3
Investing.com - Amylyx Pharmaceuticals reported on Thursday third quarter {{erl-1183198||earnings that beat analysts' forecasts and revenue that fell short of expectations. Amylyx...
Strong Buy
or
Amylyx Pharmaceuticals News & Analysis
-
-
Amylyx Pharmaceuticals, Inc. Tops Q3 EPS by 1c
Amylyx Pharmaceuticals, Inc. (AMLX) reported Q3 EPS of ($0.92), $0.01 better than the analyst estimate of ($0.93). Revenue for the quarter came in at $350 thousand versus the consensus...
-
Amylyx (NASDAQ:AMLX) Falls on News of Stock Offering of 6M Shares
On Tuesday, Amylyx Pharmaceuticals (NASDAQ:AMLX) announced a common stock offering of 6 million shares. The company stated that it intends to grant the underwriters a 30-day option to buy up...
-
After-Hours Movers: Emerson Gains on Asset Sale Talk, PG&E Falls on Block Sale
After-Hours Stock Movers: Emerson Electric (NYSE:EMR) 4% HIGHER; Blackstone (NYSE:BX) in talks to acquire certain Emerson Electric assets for $5 billion-$10 billion - Bloomberg Amylyx...
-
Nike, Rent-A-Center Fall Premarket; Amylyx, Micron and Meta Platforms Rise
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Friday, September 30th. Please refresh for updates. Nike (NYSE:NKE) stock fell over 11% after the world’s...
-
Dow Futures Rise 115 Pts; Fed's Favorite Inflation Gauge Due
By Peter Nurse Investing.com -- U.S. stocks are seen opening higher Friday, bouncing from the previous session's sharp losses ahead of key inflation data with a difficult month drawing to a...
-
After-Hours Movers 09/29: Nike, Micron Fall Post Earnings
After-Hours Stock MoversRent-A-Center, Inc. (NASDAQ/NGS: RCII) 17% LOWER; lowers third-quarter guidance.Nike (NKE) 10% LOWER; reported Q1 EPS of $0.93, $0.01 better than the analyst estimate...
-
FDA Panel Votes in Favor of Amylyx Pharmaceuticals' AMX0035 ALS Drug
By Sam Boughedda Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) shares surged Thursday after it announced that the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous...
-
Pre-Open Movers: Amylyx Surges on FDA Panel Backing, American Eagle Falls Post EPS
Pre-Open Stock Movers: Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) 75% HIGHER; announced today that the U.S. Food and Drug Administrations (FDA) Peripheral and Central Nervous System Drugs...
-
Amylyx Slumps as FDA Panel Against OK to Neurodegenerative Drug
By Dhirendra Tripathi Investing.com – Amylyx Pharmaceuticals (NASDAQ:AMLX) stock plunged more than 21% Thursday after an FDA panel voted against recommending the approval of an...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.27%
Investing.com – U.S. equities were higher at the close on Monday, as gains in the Consumer Goods, Consumer Services and Technology sectors propelled shares higher. At the close in NYSE, the...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
